Accel Wealth Management Purchases Shares of 43,955 FibroGen, Inc. (NASDAQ:FGEN)

Accel Wealth Management purchased a new stake in FibroGen, Inc. (NASDAQ:FGEN) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 43,955 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Armistice Capital LLC lifted its position in shares of FibroGen by 23.7% during the fourth quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock worth $8,654,000 after purchasing an additional 1,872,000 shares in the last quarter. Pennant Investors LP acquired a new position in shares of FibroGen during the fourth quarter worth approximately $681,000. Public Employees Retirement System of Ohio lifted its holdings in FibroGen by 1,472.7% in the third quarter. Public Employees Retirement System of Ohio now owns 176,593 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 165,364 shares during the period. Algert Global LLC lifted its holdings in FibroGen by 488.4% in the third quarter. Algert Global LLC now owns 161,550 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 134,094 shares during the period. Finally, Lighthouse Investment Partners LLC acquired a new position in FibroGen in the fourth quarter valued at approximately $136,000. 72.71% of the stock is currently owned by institutional investors and hedge funds.

FibroGen Stock Down 7.0 %

Shares of NASDAQ:FGEN opened at $0.69 on Friday. FibroGen, Inc. has a 52 week low of $0.33 and a 52 week high of $3.02. The company has a 50 day moving average price of $1.13 and a two-hundred day moving average price of $1.40.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.02). The business had revenue of $55.90 million for the quarter, compared to analysts’ expectations of $41.00 million. As a group, equities research analysts anticipate that FibroGen, Inc. will post -1.05 earnings per share for the current fiscal year.

Insider Buying and Selling at FibroGen

In other news, insider Deyaa Adib bought 22,123 shares of the stock in a transaction on Wednesday, June 12th. The stock was purchased at an average price of $1.17 per share, with a total value of $25,883.91. Following the completion of the purchase, the insider now owns 82,123 shares of the company’s stock, valued at $96,083.91. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, William Blair restated a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.